MindWalk Corp. (formerly BioStrand)

𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Earlier today, we announced our transition to MindWalk™ (NASDAQ: HYFT). The vision is now reality: one brand uniting technology, data and science to reshape discovery. MindWalk brings together IPA, BioStrand, and Talem Therapeutics under one identity: a customizable biointelligence ecosystem engineered to solve the complex. 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀: • 𝗕𝗶𝗼-𝗻𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 — LensAI™ powered by HYFT® technology, integrating 25B+ biologic connections to generate deeper insights, up to 3X faster • 𝗔 𝗼𝗻𝗲-𝗼𝗳-𝗮-𝗸𝗶𝗻𝗱 𝗱𝗮𝘁𝗮 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 — connecting sequence, structure, function, and literature to reveal hidden patterns • 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗹𝗮𝗯 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 — with a demonstrated track record of supporting 15+ programs to the clinic and achieving >98% discovery success in our leading B cell technology Patented. Validated. First-in-class. Together, we advance biologics discovery and development — providing deeper insight, greater scalability, and the potential for better patient outcomes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: 𝗺𝗶𝗻𝗱𝘄𝗮𝗹𝗸𝗔𝗜.𝗰𝗼𝗺 $IPA $HYFT #Biologics #IPA #BioStrand #Biotech #TechBio #DrugDiscovery #Antibodies

Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”. Today, IPA (ImmunoPrecise Antibodies), along with BioStrand and Talem, unify under a single identity: MindWalk. This evolution marks more than a name change. It reflects a strategic transformation into a Bio-Native AI company — built at the intersection of AI, multi-omics data, and advanced laboratory research. + New Nasdaq Ticker: HYFT + Unified Brand Identity: IPA, BioStrand, and Talem under one name — MindWalk + Business Model Shift: Transitioning from standalone wet-lab services to an integrated scalable platform company model, SaaS/DaaS offerings, and generative asset opportunities “Inspired by Darwin’s thinking path, MindWalk is about seeing what others can’t — patterns hidden in biology that point to better medicines,” said Dr. Jennifer Bath, CEO of MindWalk. “Our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.” At the core: LensAI™ powered by HYFT® technology — making biological diversity computable and accelerating discovery with clarity, speed, and depth. See full press release: ir.ipatherapeutics.com/news/news-rele… @BioStrandBV $IPA $HYFT #TechBio #Biologics #Antibodies #IPA #LensAI #DrugDiscovery

In this insightful blog by our data scientist, Sébastien Lemal, we explore AlphaFold 3’s potential and how BioStrand’s LENSᵃⁱ platform leverages these breakthroughs to accelerate biotherapeutic development. Read our blog: blog.biostrand.ai/beyond-alphafo…

2024: A Year of Transformative Progress in Biotherapeutics This year, we harnessed the power of the LENSᵃⁱ platform powered by proprietary HYFT™ pattern recognition technology and advanced simulations to tackle the most complex challenges in drug discovery. By combining innovation, collaboration, and strategic growth, we achieved milestones that are reshaping the future of biotherapeutics. ✅ Precision Oncology Breakthroughs: Leveraging HYFT-powered simulations, we developed highly specific antibodies targeting the Tumor Microenvironment (TME), advancing oncology research. ✅ LENSᵃⁱ™ Evolution: Expanded access with four models—cloud, API integrations, service offerings, and partnerships—while launching new applications like Epitope Binning & Mapping and integrating optimized tools like AlphaFold2. ✅ Key Collaborations: Partnered with BioNTech (formerly Biotheus) to engineer therapies for hypoxic tumors and InterSystems to develop Vector Search, boosting efficiency and expanding AI-powered solutions. ✅ OncoResponse Success: Rabbit anti-LILRB2 antibodies, discovered through our rabbit B Cell Select platform, progressed to IND and Phase 1/2 trials, showing early positive clinical results in safety and efficacy. ✅ Industry Recognition: BioStrand stood out among over 1,000 applicants to win the 2024 InterSystems Impact Award, highlighting our innovative approach. ✅ Transformative Research: Collaborated with Mayo Clinic on neurodegenerative disease therapies, with findings published in Autophagy. ✅ Talem Advances: Made significant strides in TATX-112, targeting TrkB for aggressive cancers. ✅ Strategic Growth: Expanded Oss and Utrecht facilities, relocated headquarters to Austin, and hosted the first TECHday in Boston, featuring live demos of LENSᵃⁱ in action. ✅ Financial Excellence: Achieved record-breaking revenue for five consecutive quarters, capping off a landmark fiscal year. As we look to 2025, we remain committed to empowering clients with transformative solutions, seamless technology integration, and groundbreaking advancements in biotherapeutics. Together, we’re redefining what’s possible. $IPA #DrugDiscovery #Antibodies #AI

@BioTechX_ has officially kicked off! Our team—Dirk Van Hyfte, Ingrid Brands, and Arnout Van Hyfte—is ready to discuss how we can help you tackle complex datasets with our innovative solutions. Stop by booth #922 to meet the team and see our live demo! @ImmunoPrecise #Data

Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr. Bath explores how unlocking the full potential of integrated data and AI analytics is aimed at revolutionizing therapeutics research, enhancing patient outcomes, and driving greater efficacy while minimizing side effects. Don’t miss the segment airing: Date: Saturday, September 28th Location: KRON-TV in San Francisco Time: between 5:30-6:00 am PDT Watch the live stream on Roku, AppleTV, or Amazon Firestick by downloading the KRONon App. @QuantumMediaLLC @AriZoldan @MarketJane $IPA #QuantumMediaGroup #Nasdaq #TechBio #DataDriven #DrugDiscovery #mAb #Antibodies

Data integration in #antibodydiscovery doesn’t have to be complex. With LENSᵃⁱ, streamline multi-omics data at the subsequence level for faster, sharper insights. From target discovery to lead optimization, we help you make informed decisions quickly. …206544.fs1.hubspotusercontent-eu1.net/hubfs/26206544…

Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its patented LENSᵃⁱ™ technology. "This marks a noteworthy milestone for the biotechnology industry, demonstrating LENSᵃⁱ's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer,” said Dr. Jennifer Bath, IPA CEO. See the full release: ir.ipatherapeutics.com/news/news-rele… $IPA #ArtificialIntelligence #AI #Antibodies #mAb #DrugDiscovery #TechBio #BioTech

In her latest blog, Julie Delanote, Data Scientist at BioStrand, explores how vector search and integrated AI technologies are transforming drug discovery by analyzing proteins at the sub-sequence level. Read the blog: blog.biostrand.ai/vector-search-…

Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Platform API by BioStrand (IPA subsidiary). This game-changing API plugs directly into large pharma or biotech existing platforms, transforming their ability to harmonize data and unlock deep insights. A huge step forward for IPA in commercialization and development timelines, enabling direct access to LENSᵃⁱ for researchers in drug discovery. We are particularly focused on optimizing electronic health record (EHR) data to provide deep insights into precision medicine. Watch the full interview: youtu.be/ku3k52oRFzU?si… $IPA #LENSai #BiotechAPI #PrecisionMedicine #Ai #LLM #EHR #Innovation #TechBio @RadiusResearch

Our latest article explores how #insilico methods enhance #drugdevelopment by providing rapid insights, early identification of potential failures, and cost-effective streamlining. Read our blog: blog.biostrand.ai/immunogenicity… #BioStrandBlogs #Immunogenicity #DrugDiscovery $IPA

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in dynamic, scaling environments. See full release: ipatherapeutics.com/news/immunopre… $IPA

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenomic Recommendations Using LENSᵃⁱ™ "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict treatment responses and adverse drug reactions. We believe that LENSᵃⁱ offers a potentially groundbreaking approach to creating an adaptive AI model that is designed to predict individual patient responses to both existing and new drugs." said Dr. Jennifer Bath, IPA President and CEO. See the full release highlighting the first integration of LENSᵃⁱ API: bit.ly/3zl7aJK $IPA @BioStrandBV #Pharmacogenomics #AI #ArtificialIntelligence #TechBio #Biotech #PersonalizedMedicine

In our latest blog post, Saskia Debergh, BioStrand computational linguist, explains why vector search is essential for finding precise information in vast data sets through advanced text analysis. Read more in our blog: blog.biostrand.ai/vector-search-… $IPA #BioStrandBlogs

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery. The launch, led by Dr. Dirk Van Hyfte, highlights the integration of BioStrand's LENSᵃⁱ™, powered by their patented HYFT® technology, with a customizable Application Programming Interface (API). These new commercial capabilities will significantly enhance BioStrand’s ability to commercialize: 1.Partnerships with large companies which may include upfront payments, clinical milestones and commercial royalties. 2.Subscription services that enable a wide range of companies to access BioStrand’s unique capabilities using integration of the software into their existing platforms. Dirk Van Hyfte will showcase the new API-based offering in a live presentation today at 2 pm ET at the InterSystems Global Summit 2024. This year’s summit expects over 1,200 attendees from more than 28 countries. See Full Release: ir.ipatherapeutics.com/news/news-rele… @InterSystems $IPA #EHR #DrugDiscovery #AI #ArtificialIntelligence #mAb @BioStrandBV

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR). BioStrand is leveraging their patented Foundation AI Model, LENSᵃⁱ™, by applying advanced Large Language Models (LLM) to capture real world data from Electronic Health Records (EHR). LENSᵃⁱ significantly enhances the analysis and integration of EHR data, enabling the integrated use of real-world data and evidence in drug discovery and the development of precision medicines. Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland See the full release: ir.ipatherapeutics.com/news/news-rele… @InterSystems $IPA #LLM #EHR #Ai #ArtificialIntelligence #LifeScience #FoundationAI #LLMS @BioStrandBV

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Technology. The 2024 Impact Award, sponsored by @InterSystems , acknowledges BioStrand’s innovative LENSᵃⁱ technology, selected from over 1,000 client projects for its remarkable contributions. The selection committee, chaired by Professor Roberto Zicari, identified BioStrand’s work based on three key criteria: makes a significant difference, breaks new ground and sets an example. Tune in to today's Main Stage live to see the award presentation from 10:30-11:00am ET : linkedin.com/events/7203844… See the full release: ir.ipatherapeutics.com/news/news-rele… $IPA #GlobalSummit24 #TechBio #VectorSearch #DrugDiscovery #Biotech #ArtificialIntelligence #Antibodies #OmicsData @BioStrandBV

Our latest blog presents a detailed case study on the LENSᵃⁱ™ approach to in silico epitope binning, validated against traditional wet lab techniques. Discover how this innovation enhances scalability and accuracy in therapeutic mAb development. blog.biostrand.ai/in-silico-epit… $IPA

Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdiscovery. Dirk Van Hyfte, BioStrand's Head of Innovation and Tom Dyar of InterSystems discuss the integration of BioStrand's LENSᵃⁱ Integrated Intelligence Technology with the InterSystems IRIS platform. This collaboration enhances vector search capabilities across various unstructured data types, optimizing efficiency and providing detailed insights at the subsequence level. A pivotal development in bridging technology with biotechnological advancements. See the full interview for a deeper exploration of these transformative developments: odbms.org/2024/05/on-usi…‌ $IPA #VectorSearch #UnstructuredData #Biotech #TechBio #Innovation @BioStrandBV @InterSystems

Explore our latest article to see how this technique improves data retrieval across diverse #unstructureddata types. Learn about its applications in #drugdiscovery and #healthcare, and why it's crucial for modern data-driven solutions. Read now: biostrand.ai/vector-search $IPA